Information  X 
Enter a valid email address

Syncona Limited (SYNC)

  Print      Mail a friend

Wednesday 31 July, 2019

Syncona Limited

Total Voting Rights

RNS Number : 4006H
Syncona Limited
31 July 2019

Syncona Limited


Total Voting Rights



31 July 2019

Pursuant to DTR 5.6.1 Syncona Limited (the "Company") announces that as at 31 July 2019 the total number of ordinary shares in issue now stands at 663,665,537 and the total number of voting rights in the Company is 663,665,537.

The Company does not hold any ordinary shares in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.





Syncona Ltd

Siobhan Weaver / Annabel Clay

Tel: +44 (0) 20 3981 7940


FTI Consulting

Brett Pollard / Natalie Garland-Collins

Tel: +44 (0) 20 3727 1000

Copies of this press release and other corporate information can be found on the company website at:  

About Syncona:


Syncona is a leading FTSE250 healthcare company focused on investing in and building global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.


We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.


We take a long-term view, underpinned by a deep pool of capital, and are established leaders in the development of genetic medicine, particularly gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t